Drug Trial Radar · NCT06336707
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,048
Planned (sponsor's estimate)
Start
Apr 11, 2024
Primary completion
Apr 8, 2026
Study completion Apr 8, 2028
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of HS-20089 in combination with other antitumor agents (Adebrelimab with or without platinum; Bevacizumab with or without platinum) in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
HS-20089Drug
Intravenous infusion
AdebrelimabDrug
Intravenous infusion
BevacizumabDrug
Intravenous infusion
Cisplatin / carboplatinDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-20089 in combination therapyTime frame: Up to day 21 from the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.